These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 31098866)

  • 41. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
    Fukui R; Watanabe T; Morimoto K; Fujimoto Y; Nagahashi M; Ishikawa E; Hirota S; Miyoshi Y
    Breast Cancer; 2023 Sep; 30(5):703-713. PubMed ID: 37115435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
    Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.
    Pruneri G; Vingiani A; Bagnardi V; Rotmensz N; De Rose A; Palazzo A; Colleoni AM; Goldhirsch A; Viale G
    Ann Oncol; 2016 Feb; 27(2):249-56. PubMed ID: 26598540
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2 - negative subtype.
    Tanaka Y; Ohno T; Kadonaga T; Kidokoro Y; Wakahara M; Nosaka K; Sakabe T; Suzuki Y; Nakamura H; Umekita Y
    Breast Cancer; 2021 Jul; 28(4):822-828. PubMed ID: 33481184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
    Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
    Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer.
    Chen Z; Chen X; Zhou E; Chen G; Qian K; Wu X; Miao X; Tang Z
    PLoS One; 2014; 9(4):e95475. PubMed ID: 24743335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
    Tsang JY; Hui SW; Ni YB; Chan SK; Yamaguchi R; Kwong A; Law BK; Tse GM
    Breast Cancer Res Treat; 2014 Jan; 143(1):1-9. PubMed ID: 24272079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancer.
    He J; Fu F; Wang W; Xi G; Guo W; Zheng L; Ren W; Qiu L; Huang X; Wang C; Li L; Kang D; Chen J
    Eur J Cancer; 2021 Sep; 154():217-226. PubMed ID: 34293665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic Factors for Luminal B-like Breast Cancer.
    Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
    Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer.
    Saber MM; El Zawahry HM; Hilal AM; Abou-Bakr AA; Namour AE; Saber MM
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):553-560. PubMed ID: 35225468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
    Bense RD; Sotiriou C; Piccart-Gebhart MJ; Haanen JBAG; van Vugt MATM; de Vries EGE; Schröder CP; Fehrmann RSN
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27737921
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Aug; 144(2):278-88. PubMed ID: 26185313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor-infiltrating lymphocytes provides recent survival information for early-stage HER2-low-positive breast cancer: a large cohort retrospective study.
    Sun T; Wang T; Li X; Wang H; Mao Y
    Front Oncol; 2023; 13():1148228. PubMed ID: 37409261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation of Preoperative Ki67 and Serum CA15.3 Levels with Outcome in Early Breast Cancers a Multi Institutional Study.
    Rasmy A; Abozeed W; Elsamany S; Baiomy ME; Nashwa A; Amrallah A; Hasaan E; Alzahrani A; Faris M; Alsaleh K; AlFaraj A
    Asian Pac J Cancer Prev; 2016; 17(7):3595-600. PubMed ID: 27510014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.